Abstract

Changing COVID-19 outcomes in patients with rheumatic disease-are we really getting better at this?

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
The role of antirheumatics in patients with COVID-19
Randy Q Cron ... Ian N Bruce
The Lancet Rheumatology | VOL. 3
Randy Q Cron, et. al.Randy Q Cron ... Ian N Bruce
30 Mar 2021
Racial and ethnic differences in COVID-19 outcomes: a call to action.
Jinoos Yazdany ... Philip C Robinson
The Lancet. Rheumatology | VOL. 4
Jinoos Yazdany, et. al.Jinoos Yazdany ... Philip C Robinson
09 Jun 2022
Divergent effects of acute versus chronic glucocorticoids in COVID-19.
Eric Morand ... Philip C Robinson
The Lancet. Rheumatology | VOL. 3
Eric Morand, et. al.Eric Morand ... Philip C Robinson
18 Jan 2021
Protecting the vulnerable: SARS-CoV-2 vaccination in immunosuppressed patients with interstitial lung disease
Elisabetta A Renzoni ... John A Mackintosh
The Lancet Respiratory Medicine | VOL. 9
Elisabetta A Renzoni, et. al.Elisabetta A Renzoni ... John A Mackintosh
17 Jul 2021
View more papers

More From: The Lancet. Rheumatology

Paper Title
Journal
Date
Author
Precision medicine in Sjögren's disease.
Saviana Gandolfo ... Francesco Ciccia
The Lancet. Rheumatology | VOL. -
Saviana Gandolfo, et. al.Saviana Gandolfo ... Francesco Ciccia
06 May 2024
Clinical assessment and management of lumbar spinal stenosis: clinical dilemmas and considerations for surgical referral.
David B Anderson ... James M Van Gelder
The Lancet. Rheumatology | VOL. -
David B Anderson, et. al.David B Anderson ... James M Van Gelder
06 May 2024
Celebrating progress in the vasculitides, old and new.
John H Stone
The Lancet. Rheumatology | VOL. 6
John H StoneJohn H Stone
01 May 2024
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Carl S Goodyear ... Victoria Walker
The Lancet. Rheumatology | VOL. -
Carl S Goodyear, et. al.Carl S Goodyear ... Victoria Walker
01 May 2024
View more papers